Emerging drugs including activator of farnesoid X receptor (Obeticholic acid), antagonist of C-C chemokine receptors type 2 and 5 (Cenicriviroc), and inhibitor of apoptosis signaling kinase-1 (Selonsertib) have been confirmed to have antifibrotic effect and will be expected to be developed as potential therapy for NAFLD cirrhosis [55]. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatotic liver disease.